SerpinPC, for Hemophilia A and B, Safely Prevents Bleeds in Phase 2a Trial

SerpinPC, for Hemophilia A and B, Safely Prevents Bleeds in Phase 2a Trial

305751

SerpinPC, for Hemophilia A and B, Safely Prevents Bleeds in Phase 2a Trial

SerpinPC, an experimental hemophilia therapy, at high dose safely reduced overall bleed rates by up to 88% and spontaneous joint bleeds by up to 94% in adults with severe hemophilia A and B, who were not using preventive treatment, according to top-line results from a Phase 2a proof-of-concept study. The therapy — administered subcutaneously, or as an under-the-skin injection — has the potential to treat all types of hemophilia regardless of disease severity or inhibitor status.…

You must be logged in to read/download the full post.